MedTrace Logo

Switch From U-100 Insulin Analog to U-500 Regular Insulin in Pumps for Type 2 Diabetes

NCT04371497 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2022-10-03

No results posted yet for this study

Summary

The aim of the study was to perform a 3-year retrospective analysis from a cohort of patients with type 2 diabetes that were treated by a pump device and were uncontrolled despite high U-100 insulin requirements. The study reports outcomes after the switch from U-100 U/ml Rapid-Acting Analog to U-500 U/ml Regular Insulin, both administered by Continuous Subcutaneous Infusion.

Conditions

Sponsors & Collaborators

  • University Hospital, Caen

    lead OTHER

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-01
Primary Completion
2017-09-30
Completion
2019-12-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04371497 on ClinicalTrials.gov